Opioids for chronic non-cancer pain

BMJ (Online)

Volumn 346, Issue 7913, 2013, Pages

  Freynhagen, Rainer ^a,b   Geisslinger, Gerd ^c   Schug, Stephan A ^d  

^a Benedictus Krankenhaus Tutzing   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CODEINE; DICLOFENAC; FENTANYL; HYDROMORPHONE; LAXATIVE; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PLACEBO; TAPENTADOL; TRAMADOL;

ANDROGEN DEFICIENCY; ARTICLE; CHRONIC PAIN; CLINICAL FEATURE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FALLING; HEALTH CARE COST; HIP OSTEOARTHRITIS; HUMAN; HYPERALGESIA; KNEE OSTEOARTHRITIS; LOW BACK PAIN; MEDICAL PRACTICE; OPIATE ADDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; SIDE EFFECT;

ANALGESICS, OPIOID; CHRONIC PAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84879380783     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f2937     Document Type: Article

References (45)

1. Scharnagel R, Kaiser U, Schütze A, Heineck R, Gossrau G, Sabatowski R. Chronic non-cancer-related pain: long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency [in German]. Schmerz 2013;27:7-19.
2. Mercadante S, Craig D, Giarratano A. US Food and Drug Administration's risk evaluation and mitigation strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. Drugs 2012;72:2327-32.
3. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981.
4. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007;105:205-21. (Pubitemid 46975867)
5. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81.
6. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006;(3):CD003726.
7. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;(3):CD006146.
8. Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ 2009;339:b3002.
9. National Institute for Health and Clinical Excellence. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. (Clinical guideline 96.) 2010. http://guidance.nice.org.uk/CG96.
10. Nüesch E, Rutjes AW, Husni E, Welch V, Jüni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;(4):CD003115.
11. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I, et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 2011;14:91-121.
12. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;(1):CD006605.
13. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125:172-9. (Pubitemid 44498976)
14. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006;260:76-87. (Pubitemid 43894073)
15. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long acting oxycodone. CMAJ 2009;181:891-6.
16. Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother 2010;24:141-4.
17. Elliot JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid therapy: a case report and review of the literature. J Opioid Manag 2011;7:145-54.
18. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep 2011;15:129-36.
19. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9:444-59. (Pubitemid 351722518)
20. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007;129:355-62. (Pubitemid 46754578)
21. Office of National Drug Control Policy. Prescription drug abuse. www.whitehouse.gov/ondcp/prescription-drug-abuse.
22. Boscarino JA, Rukstalis MR, Hoffman SN, Han JJ, Erlich PM, Ross S, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs DSM-4 diagnostic criteria. J Addict Dis 2011;30:185-94.
23. Skurtveit S, Furu K, Borchgrevink P, Handal M, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain 2011;152:1555-61.
24. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
25. Li L, Setoguchi S, Cabral H, Jick S. Opioids and risk of type 2 diabetes in adults with non-cancer pain. Pain Physician 2013;16:77-88.
26. Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008;9:425-32. (Pubitemid 351722516)
27. Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: risk factors in pain and addicted populations. J Gen Intern Med 2010;25:305-9.
28. Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Management 2011;7:235-45.
29. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011;106:835-42.
30. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007;15:957-65. (Pubitemid 47209257)
31. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317.
32. Beaulieu AD, Peloso PM, Haraoui B, Bensen W, Thomson G, Wade J, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manage 2008;13:103-10. (Pubitemid 351865292)
33. O'Donnel JB, Ekman EF, Spalding WM, Bhadra P, McCabe D, Berger MF. The effectiveness of a weak opioid medication verus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomised, double-blind, 6-week studies. J Int Med Res 2009;37:1789-802.
34. Obradovic M, Ikenberg R, Hertel N, Antoñanzas F, Gálvez R, Liedgens H. Cost-effectiveness of tapentadol in severe chronic pain in spain: a cost analysis of data from RCTs. Clin Ther 2012;34:926-43.
35. Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care 2011;17:32-40.
36. Anastassopoulos KP, Chow W, Tapia CI, Baik R, Ackerman SJ, Biondi D, et al. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manag Care Pharm 2012;18:615-26.
37. Annemanns L. Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig 2011;31:73-86.
38. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657-67.
39. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I - evidence assessment. Pain Physician 2012;15(3 suppl):S1-65.
40. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - guidance. Pain Physician 2012;15(3 suppl):S67-116.
41. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. McMaster University, 2010. http://nationalpaincentre.mcmaster.ca/opioid/cgop-a00-executive-summary.html.
42. British Pain Society. Opioids for persistent pain: good practice. British Pain Society, 2010. www.britishpainsociety.org/book-opioid-main.pdf.
43. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-42. (Pubitemid 43110296)
44. Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22:161-6.
45. Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S; WFSBP Task Force on Treatment, Guidelines for Substance Use Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry 2011;12:160-87.